Usern_member

Shaji Kumar Kumar

USERN Advisory Board

SUMMARY


The research of Shaji Kumar, M.D., focuses on development of novel drugs for treatment of myeloma. Dr. Kumar's research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.


Dr. Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes. His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.



Focus areas



  • Multiple myeloma. Dr. Kumar conducts National Institutes of Health-funded research on translation of novel therapeutic targets in multiple myeloma as well as the role of cereblon pathways in myeloma. He also receives funding from the Multiple Myeloma Research Foundation to study the relationship between molecular profiles, treatment regimens for patients with multiple myeloma and outcomes.
  • Monoclonal gammopathies. Additional research, funded by the National Cancer Institute, investigates the prevalence, onset and biomarkers for progression of monoclonal gammopathies.


Significance to patient care


Dr. Kumar's research goal is to improve the understanding of the disease biology, thereby allowing for better identification of valid therapeutic targets and, in turn, development of novel drugs.



Professional highlights



  • Editorial advisory board, The Lancet Haematology, 2014-present; Clinical Oncology News, 2011-present; Advances in Therapy journal, 2009-present; American Journal of Hematology, 2009-2011
  • Associate editor, American Journal of Hematology, 2011-present
  • Board member, European Journal of Clinical and Medical Oncology, 2011-present; Leukemia journal, 2010-present
  • Member, Institutional Review Board, Mayo Clinic, 2009-present


PROFESSIONAL DETAILS


Primary Appointment



  1. Consultant, Division of Hematology, Department of Internal Medicine

Academic Rank



  1. Professor of Medicine


EDUCATION



  1. Research Associate - Mayo Foundation Scholar(Multiple Myeloma)DFCI/Harvard Cancer Center
  2. Fellow - Hematology/ OncologyMayo Graduate School of Medicine, Mayo Clinic College of Medicine
  3. Clinical Residency - Internal MedicineMayo Graduate School of Medicine, Mayo Clinic College of Medicine
  4. Senior Resident - Medical OncologyInstitute Rotary Cancer Hospital, All-India Institute of Medical Sciences
  5. Clinical Residency - Internal MedicineAll-India Institute of Medical Sciences
  6. Internship - Rotatory InternshipAll-India Institute of Medical Sciences
  7. MB BSAll-India Institute of Medical Sciences
  8. Pre-MedicalUnion Christian College


CLINICAL STUDIES


OPEN



The purpose of this study is to evaluate the safety and tolerability of TAK-169, establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to provide a preliminary evaluation of the clinical activity of TAK-169 monotherapy in participants with relapsed or refractory multiple myeloma (RRMM).



The purpose of this study is to evaluate qualtiy of life (QOL) metrics while receiving subcutaneous (SQ) daratumumab, patient satisfaction, and patient preference for IV and/or SC therapies.




This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.



The purpose of this Phase 1 first-in human study is to evaluate the safety and preliminary efficacy of CC-98633 in adult subjects with relapsed and/or refractory MM. A challenge in CAR T-cell development is to generate a product that consistently expands, persists, and mediates durable antitumor responses after infusion. Multiple preclinical and translational studies have suggested that the differentiation state of adoptively transferred T cells can influence the ability of these cells to persist and promote durable antitumor immunity. Less differentiated T cells have shown an increased ability to proliferate, persist, and mediate responses in mouse tumor models compared to more differentiated effector memory cell subsets in certain studies.



Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.



The purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in patients with myeloma.



The purpose of this study is to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 30% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).



This phase II trial studies how well proteasome inhibitor MLN9708 works in treating patients with relapsed multiple myeloma that is not refractory to bortezomib. Proteasome inhibitor MLN9708 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.



The purpose of this study is to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.



The purpose of this study is to evaluate the safety, clinical pharmacology and clinical activity of TNB-383B, a T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Arm A will evaluate the safety, tolerability, PK and PD profiles of escalating doses of single-agent TNB-383B ranging from 25 micrograms to 40 milligrams per dose, administered once every 3 weeks (Q3W), in approximately 24 subjects. Once the maximum tolerated dose (MTD) or recommended phase 2 dose, (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the MTD/RP2D dose of TNB 383B monotherapy in approximately 48 subjects.



Here we propose an "integrative sequencing approach" utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.



The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab and lenalidomide (DR) maintenance after standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients.



This phase I/II trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with ixazomib citrate and dexamethasone may work better in treating patients with multiple myeloma.



This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as daratumumab, may block cancer growth in different ways by targeting certain cells. Giving ixazomib citrate, lenalidomide, dexamethasone, and daratumumab may work better in treating patients with newly diagnosed multiple myeloma.


CLOSED FOR ENROLLMENT



The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).



The purpose of this study is to understand more about how multiple myeloma and its treatment affect day-to-day life for patients, with particular interest in how life is affected following stem cell transplant.



To evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients will be given a 3 day course of chemotherapy followed by a single infusion of KITE-585.



The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either transplant ineligible or post autologous stem cell transplant and are relapsed/refractory.



This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, may improve bone marrow function and increase blood cell counts. Giving carfilzomib together with dexamethasone may be an effective treatment for multiple myeloma.



The purpose of this study is to compare the effect of ixazomib+dexamethasone (ixa+dex) versus pomalidomide+dexamethasone (pom+dex) on progression-free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and are refractory to lenalidomide but not refractory to proteasome inhibitors.



The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT).



This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma that has come back. Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.



The purpose of this study is to evaluate the effectiveness and safety of venetoclax, added to treatment with bortezomib and dexamethasone in patients who have returned or resistant multiple myeloma, and are considered sensitive to or have never had proteasome inhibitors.



The primary objective of this observational study is to identify the molecular profiles and clinical characteristics that define subsets of myeloma patients during the course of the disease.



This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, ≥ 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM)).



The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma.



This is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of IXAZOMIB versus placebo when added to lenalidomide and dexamethasone (LenDex) in patients with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant.



Aim 1: To identify the specific cytogenetic subtypes associated with familial predisposition in MGUS.  Aim 2: To identify the proportion of patients with high risk MGUS among patients with familial MGUS



The purpose of this study is to evaluate quality of life over time in patients with multiple myeloma or lymphoma enrolled in clinical trials compared with patients on standard therapy.



The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in subjects with relapsed or refractory multiple myeloma. This study will also assess the safety profile and PK of venetoclax in combination with dexamethasone in subjects with t(11;14)-positive multiple myeloma. The phase 2 primary objective is to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in subjects with t(11;14)-positive multiple myeloma and to evaluate patient reported outcomes.



This phase II trial studies how well pomalidomide, ixazomib citrate, and dexamethasone work in treating patients with previously treated multiple myeloma or plasma cell leukemia. Biological therapies, such as pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide, ixazomib citrate, and dexamethasone together may be more effective in treating multiple myeloma.



Does idasanutlin in combination with ixazomib and dexamethasone contribute to better outcomes for patients with multiple myeloma who have been previously treated for their disease?



This is a non-randomized, open-label study evaluating the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chronic lymphocytic leukemia (rrCLL), multiple myeloma (rrMM), or diffuse large B-cell lymphoma (rrDLBCL) in up to 138 participants from multiple sites. During an initial Dose Evaluation phase (first 2 cycles) to determine Dose Limiting Toxicities (DLTs), dose combinations of pembrolizumab 200 mg followed by dinaciclib 7 mg/m^2, pembrolizumab 200 mg followed by dinaciclib 10 mg/m^2, and pembrolizumab 200 mg followed by dinaciclib 14 mg/m^2 will be evaluated. Following safety review of the Dose Evaluation Phase, approximately 30 participants each will be enrolled in rrCLL, rrMM, or DLBCL cohorts during the Signal Detection phase. For each disease type objective response rate (ORR) will be determined by disease specific criteria.



This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with relapsed multiple myeloma. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer cells.



This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as daratumumab, may block cancer growth in different ways by targeting certain cells. Giving ixazomib citrate, lenalidomide, dexamethasone, and daratumumab may work better in treating patients with newly diagnosed multiple myeloma.



This phase II trial studies how well proteasome inhibitor MLN9708 works in treating patients with relapsed multiple myeloma that is not refractory to bortezomib. Proteasome inhibitor MLN9708 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.



This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma.



The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma.



This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells



PUBLICATIONS



  1. Parmar H, Gertz M, Anderson EI, Kumar S, Kourelis TV. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. Blood Adv. 2021 Apr 13; 5 (7):1797-1804

    View PubMed
  2. Muchtar E, Dispenzieri A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Leung N, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Fonder A, Hobbs M, Go RS, Rajkumar SV, Kyle RA, Hogan WJ, Gertz MA. Second stem cell transplantation for relapsed refractory light chain (AL) amyloidosis. Transplant Cell Ther. 2021 Apr 8 Epub 2021 Apr 08

    View PubMed
  3. Drosou ME, Vaughan LE, Muchtar E, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kapoor P, Kourelis T, Kumar S, Kyle RA, Lacy MQ, Lin Y, Lopez CL, Lust JA, Rajkumar SV, Russell SJ, Sidana S, Siddiqui MA, Sidiqi MH, Warsame R, Leung N. Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. Am J Hematol. 2021 Apr 1; 96 (4):446-454 Epub 2021 Jan 28

    View PubMed
  4. Vaxman I, Sidiqi MH, Al Saleh AS, Kumar S, Muchtar E, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Leung N, Gonsalves W, Kourelis T, Warsame R, Hogan W, Gertz M. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplant. 2021 Apr; 56 (4):928-935 Epub 2020 Nov 18

    View PubMed
  5. Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol. 2021 Apr 1; 96 (4):418-427 Epub 2021 Jan 19

    View PubMed
  6. Parmar H, Al Saleh AS, Visram A, Warsame R, Kourelis T, Gonsalves W, Dingli D, Muchtar E, Hayman S, Kapoor P, Buadi F, Dispenzieri A, Lacy M, Gertz M, Kumar S. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Transplant Cell Ther. 2021 Apr; 27 (4):309.e1-309.e5 Epub 2020 Dec 17

    View PubMed
  7. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021 Mar 29 [Epub ahead of print]

    View PubMed
  8. Facon T, Venner CP, Bahlis NJ, Offner F, White D, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, Kumar SK, Richardson PG, Rajkumar SV. Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. Blood. 2021 Mar 24 [Epub ahead of print]

    View PubMed
  9. Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, Patnaik M, Kumar S, Gertz M, Chen D, Shah MV. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J 2021 Mar 19; 11 (3):63
    View PubMed
  10. Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am J Hematol. 2021 Mar 18 [Epub ahead of print]
    View PubMed
  11. Goldman-Mazur S, Kumar SK. Current approaches to management of high-risk multiple myeloma. Am J Hematol. 2021 Mar 16 [Epub ahead of print]

    View PubMed
  12. Castillo JJ, Callander NS, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 Mar 11 [Epub ahead of print]

    View PubMed
  13. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Mar 4; 11 (3):50 Epub 2021 Mar 04
    View PubMed
  14. Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, Dean PG, Dispenzieri A, Dingli D, El Ters M, Gertz MA, Hatem A, Kapoor P, Khamash H, Kourelis T, Kumar S, Lorenz EC, Mai M, Muchtar E, Murray DL, Prieto M, Schinstock CA, Stegall MD, Warsame R, Leung N. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney Int. 2021 Mar; 99 (3):707-715 Epub 2020 July 23

    View PubMed
  15. Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Leung N, Buadi FK, Dingli D, Hayman SR, Go RS, Kapoor P, Gonsalves W, Kourelis TV, Warsame R, Hwa YL, Lisa Hwa Y, Fonder A, Hobbs M, Russell S, Lust JA, Siddiqui M, Vincent Rajkumar S, Kyle RA, Dispenzieri A. Characterization and prognostic implication of delayed complete response in AL amyloidosis. Eur J Haematol. 2021 Mar; 106 (3):354-361 Epub 2020 Dec 04

    View PubMed
  16. Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, Kumar S. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2021 Mar 1; 96 (3):330-337 Epub 2021 Jan 13

    View PubMed
  17. Muchtar E, Dispenzieri A, Magen H, Grogan M, Mauermann M, McPhail ED, Kurtin PJ, Leung N, Buadi FK, Dingli D, Kumar SK, Gertz MA. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2021 Mar; 289 (3):268-292 Epub 2020 Sept 14
    View PubMed
  18. Nandakumar B, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Go RS, Jevremovic D, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clin Proc. 2021 Mar; 96 (3):677-687

    View PubMed
  19. Visram A, Dasari S, Anderson E, Kumar S, Kourelis TV. Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. Blood Cancer J. 2021 Mar 1; 11 (3):45 Epub 2021 Mar 01
    View PubMed
  20. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, Joao C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Blade J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 Mar; 22 (3):e105-e118

    View PubMed
  21. Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A. Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. Transplant Cell Ther. 2021 Mar; 27 (3):264.e1-264.e7 Epub 2020 Dec 16
    View PubMed
  22. Visram A, Vaxman I, S Al Saleh A, Parmar H, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Warsame R, Kourelis T, Siddiqui M, Gonsalves W, Muchtar E, Lust JA, Leung N, Kyle RA, Murray D, Rajkumar SV, Kumar S. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia. 2021 Feb 23 [Epub ahead of print]

    View PubMed
  23. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Lust JA, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv. 2021 Feb 23; 5 (4):1029-1036

    View PubMed
  24. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK. Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv. 2021 Feb 23; 5 (4):1097-1101

    View PubMed
  25. Karam D, Kumar S. Post-Transplant Maintenance Treatment Options in Multiple Myeloma. Oncol Ther. 2021 Feb 21 [Epub ahead of print]

    View PubMed
  26. Evans LA, Go R, Warsame R, Nandakumar B, Buadi FK, Dispenzieri A, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Kourelis TV, Russell S, Lust JA, Lin Y, Siddiqui M, Kyle RA, Gertz MA, Rajkumar SV, Kumar S, Gonsalves WI. The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clin Lymphoma Myeloma Leuk. 2021 Feb 17 [Epub ahead of print]
    View PubMed
  27. Vaxman I, Visram A, Pasvolsky O, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Kyle R, Kapoor P, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M. Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leuk Lymphoma. 2021 Feb; 62 (2):316-322 Epub 2020 Oct 29
    View PubMed
  28. Abdallah N, Muchtar E, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Pruthi RK, Gertz MA, Kumar SK. Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clin Proc. 2021 Feb; 96 (2):377-387
    View PubMed
  29. Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 Feb 1; 11 (2):24 Epub 2021 Feb 01

    View PubMed
  30. Pang L, Rajkumar SV, Kapoor P, Buadi F, Dispenzieri A, Gertz M, Lacy M, Kyle R, Kumar S. Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer J. 2021 Feb 1; 11 (2):26 Epub 2021 Feb 01
    View PubMed
  31. Abeykoon JP, Wu X, Nowakowski KE, Dasari S, Paludo J, Weroha SJ, Hu C, Hou X, Sarkaria JN, Mladek AC, Phillips JL, Feldman AL, Ravindran A, King RL, Boysen J, Stenson MJ, Carr RM, Manske MK, Molina JR, Kapoor P, Parikh SA, Kumar S, Robinson SI, Yu J, Boughey JC, Wang L, Goetz MP, Couch FJ, Patnaik MM, Witzig TE. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. Blood. 2021 Jan 28; 137 (4):513-523

    View PubMed
  32. Kumar S, Fu A, Niesvizky R, Jagannath S, Boccia R, Raje N. Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Adv. 2021 Jan 26; 5 (2):367-376

    View PubMed
  33. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 Jan 20; 39 (3):227-237 Epub 2020 Dec 16

    View PubMed
  34. Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 Jan; 35 (1):18-30 Epub 2020 Aug 11
    View PubMed
  35. Bansal R, Kimlinger T, Gyotoku KA, Smith M, Rajkumar V, Kumar S. Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers. Clin Lymphoma Myeloma Leuk. 2021 Jan; 21 (1):e48-e51 Epub 2020 Aug 05
    View PubMed
  36. Kaya EA, Baughn LB, Pham T, Ketterling RP, Kumar SK, Jevremovic D. Lymphoma-like double-hit genetic abnormalities (MYC/IGH and IGH/BCL2) in a case of non-secretory multiple myeloma. Leuk Lymphoma 2021 Jan; 62 (1):243-246 Epub 2020 Sept 21
    View PubMed
  37. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, Garcia Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 Dec 24; 136 (26):3033-3040

    View PubMed
  38. Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res. 2020 Dec 15; 26 (24):6581-6588 Epub 2020 Oct 02

    View PubMed
  39. Gonsalves WI, Jang JS, Jessen E, Hitosugi T, Evans LA, Jevremovic D, Pettersson XM, Bush AG, Gransee J, Anderson EI, Kumar SK, Nair KS. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab. 2020 Dec 11; 8 (1):29
    View PubMed
  40. Visram A, Al Saleh AS, Parmar H, McDonald JS, Lieske JC, Vaxman I, Muchtar E, Hobbs M, Fonder A, Hwa YL, Buadi FK, Dingli D, Lacy MQ, Dispenzieri A, Kapoor P, Hayman SR, Warsame R, Kourelis TV, Siddiqui M, Gonsalves WI, Lust JA, Kyle RA, Vincent Rajkumar S, Gertz MA, Kumar SK, Leung N. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. Blood Cancer J. 2020 Dec 11; 10 (12):124

    No items yet!

    No items yet!

Your experience on this site will be improved by allowing cookies.